The current stock price of MEDP is 608.89 USD. In the past month the price increased by 11.09%. In the past year, price increased by 73.54%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 27.71 | 233.21B | ||
| DHR | DANAHER CORP | 30.69 | 167.12B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 202.14 | 61.43B | ||
| IQV | IQVIA HOLDINGS INC | 20.68 | 40.96B | ||
| A | AGILENT TECHNOLOGIES INC | 26.45 | 41.84B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 35.5 | 30.34B | ||
| WAT | WATERS CORP | 31.54 | 23.84B | ||
| ILMN | ILLUMINA INC | 33.74 | 22.48B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 39.72 | 20.20B | ||
| TEM | TEMPUS AI INC | N/A | 12.37B | ||
| RVTY | REVVITY INC | 21.93 | 11.91B | ||
| CRL | CHARLES RIVER LABORATORIES | 20.48 | 10.64B |
Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company is headquartered in Cincinnati, Ohio and currently employs 6,200 full-time employees. The company went IPO on 2016-08-11. The firm partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The firm also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
MEDPACE HOLDINGS INC
5375 Medpace Way
Cincinnati OHIO 45227 US
CEO: August J. Troendle
Employees: 6200
Phone: 15135799911
Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company is headquartered in Cincinnati, Ohio and currently employs 6,200 full-time employees. The company went IPO on 2016-08-11. The firm partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The firm also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
The current stock price of MEDP is 608.89 USD. The price increased by 3.76% in the last trading session.
MEDP does not pay a dividend.
MEDP has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
The PE ratio for MEDPACE HOLDINGS INC (MEDP) is 42.58. This is based on the reported non-GAAP earnings per share of 14.3 and the current share price of 608.89 USD.
MEDPACE HOLDINGS INC (MEDP) currently has 6200 employees.
You can find the ownership structure of MEDPACE HOLDINGS INC (MEDP) on the Ownership tab.
ChartMill assigns a technical rating of 9 / 10 to MEDP. When comparing the yearly performance of all stocks, MEDP is one of the better performing stocks in the market, outperforming 92.38% of all stocks.
ChartMill assigns a fundamental rating of 7 / 10 to MEDP. MEDP gets an excellent profitability rating and is at the same time showing great financial health properties.
Over the last trailing twelve months MEDP reported a non-GAAP Earnings per Share(EPS) of 14.3. The EPS increased by 25.22% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 18.36% | ||
| ROA | 24.7% | ||
| ROE | 147.46% | ||
| Debt/Equity | 0 |
18 analysts have analysed MEDP and the average price target is 550.48 USD. This implies a price decrease of -9.59% is expected in the next year compared to the current price of 608.89.
For the next year, analysts expect an EPS growth of 19.51% and a revenue growth 19.17% for MEDP